toxylact: a02aa01 magnesium carbonate

The first professional lActological database in the word

Magnesium carbonate (ATC A02AA01) is considered compatible with breastfeeding when used in usual oral doses as an antacid or laxative, with a very low toxicological risk for healthy term infants and some caution only with chronic high-dose use or in premature or renally impaired infants.

General information

Magnesium carbonate is a basic hydrated magnesium carbonate or normal hydrated magnesium carbonate containing the equivalent of about 40–43.5% magnesium oxide. It belongs to the ATC group A02A “Antacids”, subgroup A02AA “Magnesium compounds”, with magnesium carbonate classified specifically as A02AA01. Orally, it acts by neutralising gastric acid and by the osmotic effect of unabsorbed magnesium ions in the intestinal lumen.

Indications include treatment or prevention of hypomagnesaemia, use as an osmotic laxative, and, less commonly, as a stand‑alone antacid for dyspepsia and gastro‑oesophageal reflux symptoms. Because of its limited oral bioavailability, systemic magnesium exposure from usual doses in individuals with normal renal function is modest.

Pharmacology and toxicology

Ingested magnesium carbonate dissociates in the gastrointestinal tract, releasing magnesium ions that are only partially absorbed; the remainder remains in the gut and contributes to its laxative effect. Poor gastrointestinal absorption explains why magnesium‑containing antacids and laxatives are regarded as safe and are widely used, even during breastfeeding. In patients with normal kidney function, excess absorbed magnesium is efficiently excreted in the urine, making clinically significant hypermagnesaemia uncommon at therapeutic doses.

Toxicity is mainly related to excessive or chronic intake, especially in the presence of renal impairment, leading to hypermagnesaemia with symptoms such as nausea, vomiting, hypotension, bradycardia, and central nervous system depression. Premature or very young infants are theoretically more susceptible because of higher intestinal permeability and immature renal function, which can increase magnesium absorption and reduce clearance. For these reasons, chronic high‑dose or unnecessary prolonged administration should be avoided, and vulnerable dyads (preterm infants, maternal renal failure) need individual risk–benefit assessment.

Use during lactation

Magnesium does not significantly concentrate in human milk; typical magnesium concentrations in mature milk average around 31 mg/L (range about 15–64 mg/L) and are not substantially affected by maternal magnesium intake within normal limits. Because oral bioavailability of magnesium salts is low and transfer from maternal plasma to milk is limited, the additional exposure of the breastfed infant from maternal therapeutic use of magnesium carbonate is minimal. Lactation databases and breastfeeding‑focused resources classify magnesium carbonate as “Very Low Risk / compatible with breastfeeding”, recommending only that chronic or excessive use be avoided.

Magnesium‑containing antacids and similar products are described as poorly absorbed from the gut and safe to take during breastfeeding, with laxative effects occurring mainly in the mother if doses are excessive. International and national guidance on magnesium intake in lactating women generally supports daily intakes in the range of roughly 300–360 mg elemental magnesium from all sources, which can include dietary magnesium and, if needed, supplements or antacids, provided recommended doses are not exceeded. When used as indicated and for short periods, clinically relevant effects on milk composition or on a healthy term infant are not expected.

Toxicological risk during breastfeeding

From a toxico‑lactological perspective, magnesium carbonate carries a very low toxicological risk in breastfeeding when used at standard antacid or laxative doses and for limited durations. The risk profile is driven not by direct milk transfer of the parent compound, but by systemic accumulation of magnesium in situations of impaired renal clearance or excessive dosing, which might secondarily increase the infant’s exposure through milk. Therefore, particular caution is advised in mothers with significant renal dysfunction, in whom the threshold for hypermagnesaemia is lower.

In healthy term infants, the minimal additional magnesium delivered via breast milk under maternal therapeutic use is unlikely to cause adverse effects, and no specific adverse reactions in breastfed infants have been documented with appropriate use of magnesium salts. A relative increase in risk can be postulated for premature or very low birth weight infants because of higher intestinal absorption and immature kidney function, so in such dyads it is prudent to avoid prolonged high‑dose maternal treatment and to monitor the infant for hypotonia, poor feeding, or unusual somnolence if exposure is sustained. Overall, existing evidence and expert classifications support the conclusion that magnesium carbonate is compatible with breastfeeding, with recommendations to avoid chronic misuse, respect usual dose limits, and individualise assessment in high‑risk clinical situations.

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.